Inicio › Cáncer de pulmón de células no pequeñas › Texas
Ensayos clínicos de Cáncer de pulmón de células no pequeñas en Texas
213 estudios sobre Cáncer de pulmón de células no pequeñas buscan participantes en Texas.
Ciudades en Texas
- Houston143 estudios
- San Antonio60 estudios
- Dallas53 estudios
- Austin29 estudios
- Irving23 estudios
- Fort Worth20 estudios
- Tyler19 estudios
- The Woodlands15 estudios
- League City13 estudios
- Amarillo9 estudios
- Abilene8 estudios
- Sugar Land8 estudios
- El Paso6 estudios
- Lubbock5 estudios
- Plano4 estudios
- Denton4 estudios
- Waco4 estudios
- Round Rock4 estudios
- Odessa4 estudios
- Longview4 estudios
- Arlington4 estudios
- Killeen4 estudios
- Midland3 estudios
- Denison3 estudios
- Pearland3 estudios
- Wichita Falls3 estudios
- Beaumont3 estudios
- Richardson3 estudios
Texto oficial del estudio (inglés)
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Oncology Consultants PA, Houston
- University of Texas MD Anderson Cancer Center, Houston
ReclutandoFase 3
Edades de 18 a 100 · Todos los sexos · Actualizado el 13 nov 2026 · NCT05920356A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- Next Oncology - Austin, Austin
- Next Oncology - Houston, Houston
- Next Oncology - Dallas, Irving
- y 1 más
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 nov 2026 · NCT07488676A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
- START Fort Worth, Fort Worth
- MD Anderson Cancer Center, Houston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 nov 2026 · NCT07659782A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
- University of Texas M. D. Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 nov 2026 · NCT07111520Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- University of Texas MD Anderson Cancer Center, Houston
- Local Institution - 0173, San Antonio
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT07100080This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- The University of Texas, MD Anderson Cancer Center - Woodlands, Conroe
- Renovatio Clinical - El Paso, El Paso
- The University of Texas MD Anderson Cancer Center Diagnostic Imaging, Houston
- y 10 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06758401BostonGene and Exigent Genomic INsight Study
- Oncology Consultants, Houston
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06272864Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Hendrick Medical Center, Abilene
- Houston Methodist San Jacinto Hospital, Baytown
- Parkland Memorial Hospital, Dallas
- y 7 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT04267848A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer
- MD Anderson Cancer Center, Houston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT07133425A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- NEXT Austin, Austin
- START Center for Clinical Research, Fort Worth
- University of Texas MD Anderson Cancer Center, Houston
- y 2 más
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06270706A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Oncology Consultants P.A. ( Site 0113), Houston
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06345729Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- Mary Crowley Cancer Research Center, Dallas
- The University of Texas MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT04886804A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
- NEXT Dallas - Oncology Department, Irving
- START | San Antonio, San Antonio
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT06914128A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- MD Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT07020221A Study of DS-3939a in Participants With Solid Tumors
- The University of Texas Md Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT07739966Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT04557449A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
- TxO Central/South, Texas Oncology -Central/South Texas, Austin
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT06868485A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- NEXT Texas LLC - Austin, Austin
- START Dallas Fort Worth, LLC, Fort Worth
- MD Anderson, Houston
- y 4 más
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT07503808Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
- Texas Oncology, Beaumont
- Texas Oncology - DFW, Dallas
- Texas Oncology - San Antonio, San Antonio
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT07680790Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Research Site, Austin
- Research Site, Denton
- Research Site, Plano
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT07291037LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- Old Parkland Hospital Hematology Oncology Clinic, Dallas
- UT Southwestern Medical Center, Dallas
- DHR Health Oncology Institute, Edinburg
- y 3 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT06216301A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Texas Oncology - DFW ( Site 8103), Dallas
- UT Southwestern Medical Center ( Site 0190), Dallas
- Houston Methodist Cancer Center ( Site 0191), Houston
- y 5 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 nov 2026 · NCT06623422A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- University of Texas-MD Anderson Cancer Center ( Site 3283), Houston
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 nov 2026 · NCT07513376A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Texas Oncology - West Texas, Abilene
- University of Texas MD Anderson Cancer Center, Houston
- Local Institution - 0517, Houston
- y 1 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 nov 2026 · NCT06561386A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
- Texas Oncology-Longview Cancer Center, Longview
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 nov 2026 · NCT07566052A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas at Tyler, Tyler
ReclutandoFase 1
Edades de 18 a 99 · Todos los sexos · Actualizado el 6 nov 2026 · NCT06983743Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- The University of Texas Health Science Center at Tyler, Tyler
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 nov 2026 · NCT04198766A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Texas Oncology - West Texas, Abilene
- Texas Oncology-Northeast Texas, Allen
- Texas Oncology-West Texas, Amarillo
- y 61 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT07144280A 2-part Phase 1/2 Open-label Trial on ODM-212
- START Dallas-Fort Worth, Fort Worth
- NEXT Oncology, Irving
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT07563738A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center - Conroe, Conroe
- University of Texas MD Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
- y 3 más
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT07090499A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- The University of Texas Southwestern Medical Center at Dallas, Dallas
- Renovatio Clinical - El Paso, El Paso
- JPS Health Network, Fort Worth
- y 5 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT06793215A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
- MD Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT05789082A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Texas Oncology - Amarillo Cancer Center, Amarillo
- Texas Oncology-Austin Central, Austin
- Texas Oncology, Denton
- y 4 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT07361497A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University of Texas MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics (START), San Antonio
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06465069Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- The Center for Cancer and Blood Disorders, Fort Worth
- Kelsey-Seybold Clinic, Houston
- Houston Methodist Hospital, Houston
- y 4 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06890598A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
- The University of Texas - M.D. Anderson Cancer Center, Houston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06706076Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Texas Oncology, Abilene
- Texas Oncology - Central / South Texas, Austin
- Mary Crowley Cancer Research, Dallas
- y 3 más
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT05579366A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- The University of Texas - MD Anderson Cancer Center, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT06400472VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- The University of Texas MD Anderson Cancer Center (site 127), Houston
ReclutandoFase 1/2
Edades de 18 a 80 · Todos los sexos · Actualizado el 4 nov 2026 · NCT03556228SI-B036-ST-101 in Advanced/Metastatic Solid Tumors
- Mary Crowley Cancer Research, Dallas
- MD Anderson, Houston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 nov 2026 · NCT07857616De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.